Last reviewed 2026-05-28 · How we verify

Kevopril (QUINUPRAMINE)

Phase 2 active Small molecule ✓ Verified May 2026

Kevopril (generic name: QUINUPRAMINE) is a quinupramine drug. It is currently in Phase 2 development.

Kevopril is believed to work by interacting with certain receptors in the brain.

Kevopril is a small molecule medication. Its synonyms include Quinupramina, Quinupramine, and Quinupramine.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	QUINUPRAMINE
Drug class	quinupramine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your brain is like a city with many different neighborhoods. Kevopril is like a special key that unlocks certain doors in the brain, allowing different chemicals to talk to each other in new ways. This can help to calm down or change the way the brain works, which can be helpful for treating certain conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Kevopril CI brief — competitive landscape report
Kevopril updates RSS · CI watch RSS

Frequently asked questions about Kevopril

What is Kevopril?

Kevopril (QUINUPRAMINE) is a quinupramine drug.

How does Kevopril work?

Kevopril is believed to work by interacting with certain receptors in the brain.

What is the generic name of Kevopril?

QUINUPRAMINE is the generic (nonproprietary) name of Kevopril.

What drug class is Kevopril in?

Kevopril belongs to the quinupramine class. See all quinupramine drugs at /class/quinupramine.

What development phase is Kevopril in?

Kevopril is in Phase 2.

Drug class: All quinupramine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing